NCT06087965View on ClinicalTrials.gov

Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 11, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions
Intracerebral Hemorrhage
Interventions
DRUG

Fingolimod

0.5mg/day oral fingolimod over a course of 3 consecutive days

All Listed Sponsors
lead

Tang-Du Hospital

OTHER

NCT06087965 - Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage | Biotech Hunter | Biotech Hunter